Firm
Publication of the UPC’s annual report and adoption of the procedural rules of the Patent Mediation and Arbitration Centre were also among major developments
Tarun Khurana, founding partner of Khurana & Khurana, discusses juggling tasks, why every hour has a value, and the importance of ‘trusting the process’
The variety of winners demonstrates that the UPC is now a core benchmark rather than an experimental consideration, while junior lawyers are becoming more deeply involved in key work
Sheppard, which has hired 14 IP partners in the last 12 months, has cited client demand for expert counsel in SEP, ITC, and district court disputes
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesChiu-ling Lin of Saint Island International Patent & Law Offices discusses a ruling by the Supreme Administrative Court in Taiwan that highlights the importance of claim definiteness and enabling requirements in crystalline form patent cases -
Sponsored by Tilleke & GibbinsAfter decades of debate, Vietnam has recognised the need to create a court dedicated to intellectual property matters, says Loc Xuan Le of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Gün + PartnersSelin Sinem Erciyas and Zeynep Çağla Üstün explore whether Turkey, as a non-EU state party to the European Patent Convention, might still face the Unified Patent Court’s jurisdiction under EU regulations
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework
-
Sponsored by Spoor & FisherNew patent and utility model procedures and updated fees form part of a legislative update to the Bangui Agreement that became effective in the new year, explains Craig Kahn of Spoor & Fisher Jersey
-
Sponsored by MaiwaldChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access
